title: The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants.
abstract: Serum antibody responses to three Haemophilus influenzae type b (Hib) capsular polysaccharide-protein conjugate vaccine (PRP-OMP, PRP-T, and HbOC) were evaluated in 174 Philippine infants after a primary vaccination series. Children were randomized to receive one of the Hib vaccines (Hib groups) or into a control group. Vaccination was carried out at six, 10 and 14 weeks of age based on the local Expanded Program of Immunization schedule. Sera were collected at six weeks of age for the Hib groups and one month after the third dose for all subjects. Anti-Hib concentrations were determined by the Farr-type radioimmunoassay. There were no significant differences (P = 0.3626) in the prevaccination anti-Hib geometric mean concentration (GMC) among the three Hib groups. Differences in the GMC after the primary series of three doses were significant (P < 0.0001); GMC was highest for PRP-T (6.62 micrograms/ml), followed by HbOC (1.9 micrograms/ml), then PRP-OMP (1.06 micrograms/ml), and lowest for the control group (0.11 microgram/ml). We conclude that all three Hib conjugate vaccines (PRP-T, HbOC, and PRP-OMP) were immunogenic after three primary doses among Philippine infants.
authors.affiliation: Research Institute for Tropical Medicine, Manila, The Philippines.
authors.forename: M R
authors.initials: MR
authors.lastname: Capeding
authors.forename: H
authors.initials: H
authors.lastname: Nohynek
authors.forename: L G
authors.initials: LG
authors.lastname: Pascual
authors.forename: H
authors.initials: H
authors.lastname: Kayhty
authors.forename: L T
authors.initials: LT
authors.lastname: Sombrero
authors.forename: J
authors.initials: J
authors.lastname: Eskola
authors.forename: P
authors.initials: P
authors.lastname: Ruutu
mesh_terms: D000907:Antibodies, Bacterial / Q000032:analysis; D001425:Bacterial Outer Membrane Proteins / Q000009:adverse effects / Q000276:immunology; D001426:Bacterial Proteins / Q000009:adverse effects / Q000276:immunology; D006192:Haemophilus Infections / Q000276:immunology* / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007223:Infant; D011135:Polysaccharides, Bacterial / Q000009:adverse effects / Q000276:immunology; D013745:Tetanus Toxoid / Q000009:adverse effects / Q000276:immunology; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid; C061963:HibTITER protein, Haemophilus influenzae